Datasets:
allele_iedb stringclasses 37
values | allele stringclasses 37
values | peptide stringlengths 7 15 | peptide_length int64 7 15 | measurement_type stringclasses 2
values | measurement_value float64 0 14.3M | measurement_units stringclasses 1
value | assay_method stringclasses 6
values | assay_response stringclasses 2
values | pubmed_id float64 7.51M 37.8M ⌀ | parent_protein stringlengths 3 188 ⌀ | protein_accession stringlengths 6 14 | source_organism stringclasses 849
values | assay_pdb_id float64 | flagged bool 2
classes | has_structures bool 1
class | num_pdbs int64 22 25 | rosetta_best_score float64 -633.25 1.04 | rosetta_mean_score float64 -620.04 44 | pdb_dir stringlengths 24 32 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HLA-B_35_03 | B*35:03 | HPNIEEVAL | 9 | IC50 | 6.8 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,508,927 | Genome polyprotein | ACE82359.1 | hepatitis C virus genotype 1a | null | false | true | 25 | -585.842 | -565.7758 | structures/B3503/HPNIEEVAL |
HLA-B_35_03 | B*35:03 | SPGDLQTLAL | 10 | IC50 | 16,115 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,539,795 | Insulin-1 | NP_032412.3 | Mus musculus | null | false | true | 25 | -568.58 | -529.3615 | structures/B3503/SPGDLQTLAL |
HLA-B_42_01 | B*42:01 | SPGDLQTLAL | 10 | IC50 | 35 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,539,795 | Insulin-1 | NP_032412.3 | Mus musculus | null | false | true | 25 | -575.301 | -549.8056 | structures/B4201/SPGDLQTLAL |
HLA-B_42_01 | B*42:01 | GPGAGSLQPLAL | 12 | IC50 | 6,066 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,539,795 | Insulin | P01308.1 | Homo sapiens | null | false | true | 25 | -580.154 | -529.118 | structures/B4201/GPGAGSLQPLAL |
HLA-B_13_02 | B*13:02 | ELPKYGVKV | 9 | Kd | 10,000 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Large ribosomal subunit protein uL18 | A0A2R8Y4A2.1 | Homo sapiens | null | false | true | 25 | -569.14 | -529.8654 | structures/B1302/ELPKYGVKV |
HLA-B_45_01 | B*45:01 | SENERGYYI | 9 | IC50 | 336 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Liver stage antigen 1 | Q25893.1 | Plasmodium falciparum | null | false | true | 25 | -563.413 | -541.4912 | structures/B4501/SENERGYYI |
HLA-B_45_01 | B*45:01 | RENANQLVV | 9 | IC50 | 37 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Thrombospondin-related anonymous protein | AAG12328.1 | Plasmodium falciparum | null | false | true | 25 | -594.309 | -558.9796 | structures/B4501/RENANQLVV |
HLA-B_45_01 | B*45:01 | NELNYDNAGI | 10 | IC50 | 457 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Circumsporozoite protein | AAA29547.1 | Plasmodium falciparum | null | false | true | 25 | -579.154 | -542.0438 | structures/B4501/NELNYDNAGI |
HLA-B_45_01 | B*45:01 | AELLAACF | 8 | IC50 | 247 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Protein P | AAP79852.1 | Hepatitis B virus | null | false | true | 25 | -565.646 | -542.5842 | structures/B4501/AELLAACF |
HLA-B_45_01 | B*45:01 | AELLAACFA | 9 | IC50 | 6.6 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Protein P | AAP79852.1 | Hepatitis B virus | null | false | true | 25 | -587.657 | -555.0832 | structures/B4501/AELLAACFA |
HLA-B_45_01 | B*45:01 | RETVLEYLV | 9 | IC50 | 205 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Capsid protein | AAO62974.1 | Hepatitis B virus | null | false | true | 25 | -570.839 | -500.478 | structures/B4501/RETVLEYLV |
HLA-B_45_01 | B*45:01 | AEAALENLV | 9 | IC50 | 35 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Genome polyprotein | Q81495.3 | Hepatitis C virus (isolate HCV-K3a/650) | null | false | true | 25 | -575.513 | -565.832 | structures/B4501/AEAALENLV |
HLA-B_45_01 | B*45:01 | AENLYVTVF | 9 | IC50 | 69 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | null | ONTIE_0002602 | Human immunodeficiency virus 1 | null | false | true | 25 | -578.537 | -534.1985 | structures/B4501/AENLYVTVF |
HLA-B_45_01 | B*45:01 | AENLWVTVYY | 10 | IC50 | 245 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Envelope glycoprotein gp160 | AAA80623.1 | Human immunodeficiency virus 1 | null | false | true | 25 | -591.664 | -552.8358 | structures/B4501/AENLWVTVYY |
HLA-B_45_01 | B*45:01 | AENLWVTVY | 9 | IC50 | 68 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Envelope glycoprotein gp160 | AAA80623.1 | Human immunodeficiency virus 1 | null | false | true | 25 | -559.054 | -533.8975 | structures/B4501/AENLWVTVY |
HLA-B_45_01 | B*45:01 | ADKNLIKCS | 9 | IC50 | 70,000 | nM | cellular MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 19,734,234 | RING finger protein Z | AAQ55253.1 | Mammarenavirus guanaritoense | null | false | true | 25 | -574.735 | -543.7753 | structures/B4501/ADKNLIKCS |
HLA-B_45_01 | B*45:01 | FEFTSFFY | 8 | IC50 | 12,811 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | P03431.1 | Influenza A virus | null | false | true | 25 | -575.586 | -541.3988 | structures/B4501/FEFTSFFY |
HLA-B_45_01 | B*45:01 | FESKSMKL | 8 | IC50 | 53,678 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | P03431.1 | Influenza A virus | null | false | true | 25 | -587.097 | -561.1407 | structures/B4501/FESKSMKL |
HLA-B_45_01 | B*45:01 | AEIMKICST | 9 | IC50 | 139 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | AAA43637.1 | Influenza A virus | null | false | true | 25 | -588.379 | -575.9348 | structures/B4501/AEIMKICST |
HLA-B_45_01 | B*45:01 | AESRKLLLI | 9 | IC50 | 167 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | Polymerase acidic protein | NP_775531.1 | Influenza A virus | null | false | true | 25 | -564.908 | -537.6573 | structures/B4501/AESRKLLLI |
HLA-B_45_01 | B*45:01 | CEKLEQSGL | 9 | IC50 | 359 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | P03431.1 | Influenza A virus | null | false | true | 25 | -582.221 | -533.7259 | structures/B4501/CEKLEQSGL |
HLA-B_45_01 | B*45:01 | CELTDSSWI | 9 | IC50 | 139 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | Polymerase acidic protein | NP_775531.1 | Influenza A virus | null | false | true | 25 | -580.18 | -542.6047 | structures/B4501/CELTDSSWI |
HLA-B_45_01 | B*45:01 | AEIEDLIFLA | 10 | IC50 | 8.9 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | Nucleoprotein | AAK18005.1 | Influenza A virus | null | false | true | 25 | -569.83 | -540.2655 | structures/B4501/AEIEDLIFLA |
HLA-B_45_01 | B*45:01 | YERMCNILKG | 10 | IC50 | 19,823 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | Nucleoprotein | AAK18005.1 | Influenza A virus | null | false | true | 25 | -558.623 | -510.3544 | structures/B4501/YERMCNILKG |
HLA-B_45_01 | B*45:01 | AEKPKFLPDLY | 11 | IC50 | 2,929 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | Polymerase acidic protein | NP_775531.1 | Influenza A virus | null | false | true | 25 | -564.406 | -515.7918 | structures/B4501/AEKPKFLPDLY |
HLA-B_37_01 | B*37:01 | RQSSGSSSSGF | 11 | IC50 | 316.8 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | ATP-dependent RNA helicase DDX3Y | NP_004651.2 | Homo sapiens | null | false | true | 25 | -586.431 | -539.7983 | structures/B3701/RQSSGSSSSGF |
HLA-B_37_01 | B*37:01 | FQILHDRFF | 9 | IC50 | 365.3 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | null | false | true | 25 | -585.791 | -514.5398 | structures/B3701/FQILHDRFF |
HLA-B_37_01 | B*37:01 | TEAEKWPFF | 9 | IC50 | 394.2 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Sex-determining region Y protein (Fragment) | ACQ77096.1 | Tarsius lariang | null | false | true | 25 | -566.552 | -486.8687 | structures/B3701/TEAEKWPFF |
HLA-B_37_01 | B*37:01 | KVADVDLAVPV | 11 | IC50 | 906.6 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Gamma-taxilin | NP_115965.1 | Homo sapiens | null | false | true | 25 | -589.808 | -532.2005 | structures/B3701/KVADVDLAVPV |
HLA-B_37_01 | B*37:01 | IVDCLTEMYY | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | null | false | true | 25 | -566.793 | -523.2168 | structures/B3701/IVDCLTEMYY |
HLA-B_37_01 | B*37:01 | ILNRETLLDFV | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Putative gamma-taxilin 2 | AAK13476.1 | Homo sapiens | null | false | true | 25 | -572.504 | -516.4488 | structures/B3701/ILNRETLLDFV |
HLA-B_37_01 | B*37:01 | FLLPILSQIYT | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | RNA helicase | XP_001378186.1 | Monodelphis domestica | null | false | true | 25 | -569.601 | -459.0111 | structures/B3701/FLLPILSQIYT |
HLA-B_37_01 | B*37:01 | SLMASSPTSI | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Lysine-specific demethylase 5D | AAC50806.1 | Homo sapiens | null | false | true | 25 | -582.304 | -545.1512 | structures/B3701/SLMASSPTSI |
HLA-B_37_01 | B*37:01 | SLLERGQQLGV | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | [histone H3]-trimethyl-L-lysine(4) demethylase | XP_001064297.1 | Rattus norvegicus | null | false | true | 25 | -549.714 | -497.0372 | structures/B3701/SLLERGQQLGV |
HLA-B_37_01 | B*37:01 | MIKYCLLKILK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Histone demethylase UTY | NP_033510.2 | Mus musculus | null | false | true | 25 | -581.791 | -539.7794 | structures/B3701/MIKYCLLKILK |
HLA-B_37_01 | B*37:01 | GSSDFQVHFLK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | null | false | true | 25 | -556.552 | -532.7305 | structures/B3701/GSSDFQVHFLK |
HLA-B_37_01 | B*37:01 | YSLEYFQFVKK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | ubiquitinyl hydrolase 1 | XP_001366553.1 | Monodelphis domestica | null | false | true | 25 | -563.228 | -483.1645 | structures/B3701/YSLEYFQFVKK |
HLA-B_37_01 | B*37:01 | KSLTTTMQFK | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Protocadherin-11 Y-linked | NP_116753.1 | Homo sapiens | null | false | true | 25 | -581.743 | -487.2569 | structures/B3701/KSLTTTMQFK |
HLA-B_37_01 | B*37:01 | SYMMDDLELI | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | null | false | true | 25 | -545.016 | -493.8796 | structures/B3701/SYMMDDLELI |
HLA-B_37_01 | B*37:01 | YFYYNAFHWAI | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Histone demethylase UTY | AAY16579.1 | Homo sapiens | null | false | true | 25 | -581.115 | -486.819 | structures/B3701/YFYYNAFHWAI |
HLA-B_37_01 | B*37:01 | RYSHWTKL | 8 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Sex-determining region Y protein | P48046.1 | Gorilla gorilla gorilla | null | false | true | 25 | -576.454 | -553.7766 | structures/B3701/RYSHWTKL |
HLA-B_37_01 | B*37:01 | SSKMFNYFK | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Isoform 4 of Neuroligin-4, Y-linked | AAH32567.1 | Homo sapiens | null | false | true | 25 | -592.726 | -570.5129 | structures/B3701/SSKMFNYFK |
HLA-B_37_01 | B*37:01 | RMILPMSRAFR | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | NP_683745.2 | Mus musculus | null | false | true | 25 | -588.983 | -552.6933 | structures/B3701/RMILPMSRAFR |
HLA-B_37_01 | B*37:01 | ELFARSSDPR | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | null | false | true | 25 | -580.406 | -557.7733 | structures/B3701/ELFARSSDPR |
HLA-B_37_01 | B*37:01 | LVTMGTGTFGR | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Putative serine/threonine-protein kinase PRKY | O43930.1 | Homo sapiens | null | false | true | 25 | -548.624 | -522.7722 | structures/B3701/LVTMGTGTFGR |
HLA-B_37_01 | B*37:01 | LPADPASVL | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Sex-determining region Y protein (Fragment) | ABM65922.1 | Ateles geoffroyi | null | false | true | 25 | -594.867 | -574.0286 | structures/B3701/LPADPASVL |
HLA-B_37_01 | B*37:01 | MVRVLTVIKEY | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | CAA73940.1 | Homo sapiens | null | false | true | 25 | -545.741 | -506.3387 | structures/B3701/MVRVLTVIKEY |
HLA-B_37_01 | B*37:01 | YQSMIRPPY | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Amelogenin, Y isoform (Fragment) | XP_001145496.1 | Pan troglodytes | null | false | true | 25 | -561.749 | -525.1817 | structures/B3701/YQSMIRPPY |
HLA-B_37_01 | B*37:01 | VALFSSCPVAY | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9X | NP_033507.2 | Mus musculus | null | false | true | 25 | -560.655 | -532.5462 | structures/B3701/VALFSSCPVAY |
HLA-B_37_01 | B*37:01 | FPHTELANL | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | null | false | true | 25 | -579.509 | -486.606 | structures/B3701/FPHTELANL |
HLA-B_37_01 | B*37:01 | LPSCPTNFCIF | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Isoform 2 of Histone demethylase UTY | BAF85547.1 | Homo sapiens | null | false | true | 25 | -572.898 | -488.4655 | structures/B3701/LPSCPTNFCIF |
HLA-B_37_01 | B*37:01 | RPPYSSYGY | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Amelogenin, Y isoform (Fragment) | XP_001145496.1 | Pan troglodytes | null | false | true | 25 | -578.224 | -500.9122 | structures/B3701/RPPYSSYGY |
HLA-B_37_01 | B*37:01 | TFVPIAWAAAY | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Zinc finger protein Y-linked | ACL51661.1 | Callithrix jacchus | null | false | true | 25 | -556.955 | -490.3761 | structures/B3701/TFVPIAWAAAY |
HLA-B_37_01 | B*37:01 | LEYFQFVKKLL | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | ubiquitinyl hydrolase 1 | XP_001366553.1 | Monodelphis domestica | null | false | true | 25 | -539.473 | -494.0599 | structures/B3701/LEYFQFVKKLL |
HLA-B_37_01 | B*37:01 | YPDPVIKV | 8 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Small ribosomal subunit protein eS4, Y isoform 1 | EAX02770.1 | Homo sapiens | null | false | true | 25 | -606.838 | -577.7053 | structures/B3701/YPDPVIKV |
HLA-B_52_01 | B*52:01 | QGFPWDILF | 9 | IC50 | 18 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AAG26087.1 | Hepatitis delta virus | null | false | true | 25 | -548.735 | -509.6325 | structures/B5201/QGFPWDILF |
HLA-B_52_01 | B*52:01 | DRGFPWDILF | 10 | IC50 | 4,682 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AVV65245.1 | Hepatitis delta virus | null | false | true | 25 | -547.616 | -503.2128 | structures/B5201/DRGFPWDILF |
HLA-B_52_01 | B*52:01 | NQGIPWDILF | 10 | IC50 | 1,469 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | ONTIE_0003412 | Hepatitis delta virus | null | false | true | 25 | -552.953 | -497.4428 | structures/B5201/NQGIPWDILF |
HLA-B_52_01 | B*52:01 | QGFPWDMLF | 9 | IC50 | 90 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AAF13849.1 | Hepatitis delta virus | null | false | true | 25 | -565.182 | -532.5892 | structures/B5201/QGFPWDMLF |
HLA-B_52_01 | B*52:01 | RGFPWDILF | 9 | IC50 | 224 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AVV65245.1 | Hepatitis delta virus | null | false | true | 25 | -577.686 | -542.4519 | structures/B5201/RGFPWDILF |
HLA-B_52_01 | B*52:01 | QGFPWDLLF | 9 | IC50 | 135 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AAO49188.1 | Hepatitis delta virus | null | false | true | 25 | -557.888 | -513.7281 | structures/B5201/QGFPWDLLF |
HLA-B_52_01 | B*52:01 | SQGFPWDILF | 10 | IC50 | 3,657 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | P25989.1 | Hepatitis delta virus | null | false | true | 25 | -546.067 | -498.1719 | structures/B5201/SQGFPWDILF |
HLA-B_14_02 | B*14:02 | MVFGRFSFA | 9 | Kd | 1,178 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | null | Membrane protein, putative | AAU48420.1 | Burkholderia mallei ATCC 23344 | null | false | true | 25 | -566.687 | -541.4444 | structures/B1402/MVFGRFSFA |
HLA-B_14_02 | B*14:02 | FRKAQIQGL | 9 | Kd | 3,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Epstein-Barr nuclear antigen 6 | S33015 | human gammaherpesvirus 4 | null | false | true | 25 | -556.98 | -532.4776 | structures/B1402/FRKAQIQGL |
HLA-B_14_02 | B*14:02 | TGIAIIAYI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Lmo2486 protein | CAD00564.1 | Listeria monocytogenes EGD-e | null | false | true | 25 | -561.762 | -554.55 | structures/B1402/TGIAIIAYI |
HLA-B_14_02 | B*14:02 | YLDNVGVHI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Phosphoprotein | AAK55078.1 | Lyssavirus rabies | null | false | true | 25 | -593.277 | -532.3088 | structures/B1402/YLDNVGVHI |
HLA-B_14_02 | B*14:02 | TRAPAPFPL | 9 | Kd | 565 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | DNA polymerase III subunit epsilon | AAL59738.1 | Vibrio cholerae | null | false | true | 25 | -586.426 | -542.3101 | structures/B1402/TRAPAPFPL |
HLA-B_14_02 | B*14:02 | TTRAVNMEV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Gluconate 2-dehydrogenase | AAL53555.1 | Brucella melitensis bv. 1 str. 16M | null | false | true | 25 | -559.67 | -539.5118 | structures/B1402/TTRAVNMEV |
HLA-B_14_02 | B*14:02 | KQIVIINPM | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | GlcNAc phosphomutase | AAO10081.1 | Vibrio vulnificus CMCP6 | null | false | true | 25 | -590.347 | -576.5902 | structures/B1402/KQIVIINPM |
HLA-B_14_02 | B*14:02 | MYPFIFFIV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Hypothetical membrane spanning protein | AAO90371.1 | Coxiella burnetii RSA 493 | null | false | true | 25 | -577.271 | -510.7029 | structures/B1402/MYPFIFFIV |
HLA-B_14_02 | B*14:02 | WAIQCYTGV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Na+/H+ antiporter NhaC | AAO07968.1 | Vibrio vulnificus CMCP6 | null | false | true | 25 | -566.022 | -530.0554 | structures/B1402/WAIQCYTGV |
HLA-B_14_02 | B*14:02 | ELAPIRVNA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Dehydrogenases with different specificities | BAC97625.1 | Vibrio vulnificus YJ016 | null | false | true | 25 | -592.077 | -507.6166 | structures/B1402/ELAPIRVNA |
HLA-B_14_02 | B*14:02 | FTWQHNYYL | 9 | Kd | 20,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | 40S ribosomal protein S10 | EAK87991.1 | Cryptosporidium parvum Iowa II | null | false | true | 25 | -585.847 | -542.8509 | structures/B1402/FTWQHNYYL |
HLA-B_14_02 | B*14:02 | NGNFNFERV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Glucosidase II subunit alpha | EAK89133.1 | Cryptosporidium parvum Iowa II | null | false | true | 25 | -550.607 | -524.9519 | structures/B1402/NGNFNFERV |
HLA-B_14_02 | B*14:02 | SVFELSNFA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | null | BAC93293.1 | Vibrio vulnificus YJ016 | null | false | true | 25 | -567.053 | -502.4737 | structures/B1402/SVFELSNFA |
HLA-B_14_02 | B*14:02 | TVFRNQNRV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Shares a domain with a conserved HREF motif with the CWF15 protein that is involved in mRNA splicing | EAK89397.1 | Cryptosporidium parvum Iowa II | null | false | true | 25 | -572.836 | -367.5504 | structures/B1402/TVFRNQNRV |
HLA-B_14_02 | B*14:02 | ERAFQNWSV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | DNA topoisomerase | EAL47247.1 | Entamoeba histolytica HM-1:IMSS | null | false | true | 25 | -577.903 | -513.3426 | structures/B1402/ERAFQNWSV |
HLA-B_14_02 | B*14:02 | FTLINWRSV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | tRNA pseudouridine synthase, putative | EAL50898.1 | Entamoeba histolytica HM-1:IMSS | null | false | true | 25 | -585.182 | -550.2807 | structures/B1402/FTLINWRSV |
HLA-B_14_02 | B*14:02 | IESNPLFPV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Dedicator of cytokinesis protein | EAL49146.1 | Entamoeba histolytica HM-1:IMSS | null | false | true | 25 | -581.624 | -549.9445 | structures/B1402/IESNPLFPV |
HLA-B_14_02 | B*14:02 | NPAACSYMV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | EAL50926.1 | Entamoeba histolytica HM-1:IMSS | null | false | true | 25 | -572.187 | -437.9042 | structures/B1402/NPAACSYMV |
HLA-B_14_02 | B*14:02 | EGAGIDDPV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | AcrB/AcrD/AcrF family protein | EAL56425.1 | Campylobacter coli RM2228 | null | false | true | 25 | -578.348 | -551.3372 | structures/B1402/EGAGIDDPV |
HLA-B_14_02 | B*14:02 | FFSPFFFSL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Clustered-asparagine-rich protein | CAJ20722.1 | Toxoplasma gondii RH | null | false | true | 25 | -569.981 | -487.2329 | structures/B1402/FFSPFFFSL |
HLA-B_14_02 | B*14:02 | FMVYVPLPA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Isocitrate dehydrogenase kinase/phosphatase | ABG16349.1 | Yersinia pestis Nepal516 | null | false | true | 25 | -587.954 | -575.4614 | structures/B1402/FMVYVPLPA |
HLA-B_14_02 | B*14:02 | YQAENSTAE | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Protein bdm | ABG69490.1 | Escherichia coli 536 | null | false | true | 25 | -581.016 | -498.8863 | structures/B1402/YQAENSTAE |
HLA-B_14_02 | B*14:02 | FGALFMWLL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Cytochrome oxidase subunit | ABF04835.1 | Shigella flexneri 5 str. 8401 | null | false | true | 25 | -584.931 | -567.9209 | structures/B1402/FGALFMWLL |
HLA-B_14_02 | B*14:02 | KQIGGTLFE | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Glutamate 5-kinase | CAL34268.1 | Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 | null | false | true | 25 | -573.427 | -473.6706 | structures/B1402/KQIGGTLFE |
HLA-B_14_02 | B*14:02 | QQRPDLILV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Endonuclease V | CAL22320.1 | Yersinia pestis CO92 | null | false | true | 25 | -543.51 | -471.85 | structures/B1402/QQRPDLILV |
HLA-B_14_02 | B*14:02 | GVDGGWQAL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | UDP-N-acetylmuramate--L-alanyl-gamma-D-glutamyl-meso-2,6-diaminoheptandioate ligase | ABM49996.1 | Burkholderia mallei SAVP1 | null | false | true | 25 | -569.032 | -530.2502 | structures/B1402/GVDGGWQAL |
HLA-B_14_02 | B*14:02 | MGMEQTMSV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | MSHA biogenesis protein MshN | EAX58236.1 | Vibrio cholerae 2740-80 | null | false | true | 25 | -570.395 | -536.4926 | structures/B1402/MGMEQTMSV |
HLA-B_14_02 | B*14:02 | NVMDPMHGA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Iron-sulfur cluster-binding protein, rieske family | ABM49342.1 | Burkholderia mallei SAVP1 | null | false | true | 25 | -600.678 | -556.512 | structures/B1402/NVMDPMHGA |
HLA-B_14_02 | B*14:02 | RVACRDVEV | 9 | Kd | 3,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Putative cytochrome P450 140 | CAL71904.1 | Mycobacterium tuberculosis variant bovis BCG str. Pasteur 1173P2 | null | false | true | 25 | -577.677 | -528.1645 | structures/B1402/RVACRDVEV |
HLA-B_14_02 | B*14:02 | EGFDPRALI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Glycerophosphoryl diester phosphodiesterase family protein | ABQ60400.1 | Brucella ovis ATCC 25840 | null | false | true | 25 | -562.366 | -481.7314 | structures/B1402/EGFDPRALI |
HLA-B_14_02 | B*14:02 | HQFTSNPEV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | FHA domain-containing protein | EDM60245.1 | Vibrio parahaemolyticus AQ3810 | null | false | true | 25 | -598.857 | -546.5586 | structures/B1402/HQFTSNPEV |
HLA-B_14_02 | B*14:02 | MTACGRIVV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | TfuA-like core domain-containing protein | EBA41824.1 | Mycobacterium tuberculosis str. Haarlem | null | false | true | 25 | -574.499 | -513.5247 | structures/B1402/MTACGRIVV |
HLA-B_14_02 | B*14:02 | EDFEIFYNL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Ribonuclease D | ABV79247.1 | Rickettsia bellii OSU 85-389 | null | false | true | 25 | -590.307 | -547.1164 | structures/B1402/EDFEIFYNL |
HLA-B_14_02 | B*14:02 | ETVWPFFYA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Nitrate reductase | ABX61793.1 | Brucella canis ATCC 23365 | null | false | true | 25 | -567.653 | -544.3466 | structures/B1402/ETVWPFFYA |
HLA-B_14_02 | B*14:02 | FTARIIIFS | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | ABV75419.1 | Rickettsia akari str. Hartford | null | false | true | 25 | -575.874 | -493.3533 | structures/B1402/FTARIIIFS |
HLA-B_14_02 | B*14:02 | FVMPIFEQI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Prophage LambdaBa01, membrane protein | EDR16741.1 | Bacillus anthracis str. A0488 | null | false | true | 25 | -583.321 | -560.9087 | structures/B1402/FVMPIFEQI |
HLA-B_14_02 | B*14:02 | MTFPLHFRS | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | EDO77069.1 | Giardia lamblia ATCC 50803 | null | false | true | 25 | -595.791 | -562.9997 | structures/B1402/MTFPLHFRS |
HLA-B_14_02 | B*14:02 | MTYLDGHPV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | EDO78551.1 | Giardia lamblia ATCC 50803 | null | false | true | 25 | -599.185 | -572.5628 | structures/B1402/MTYLDGHPV |
pHLA Binding Affinity with Rosetta FlexPepDock Structures
Author: K. Hunter, Vanderbilt University Medical Center
License: CC BY 4.0
Metadata source: Immune Epitope Database (IEDB)
Dataset Summary
This dataset combines experimentally measured peptide–HLA (pHLA) binding affinities from the IEDB with computationally generated 3D structures produced using Rosetta FlexPepDock. It covers 37 HLA class I alleles (HLA-A and HLA-B), 14,077 unique peptides, and 49,490 peptide–allele pairs with associated docked structures.
Each peptide–allele pair with a recorded binding measurement (Kd or IC50) is linked to an ensemble of 25 Rosetta FlexPepDock decoy structures, along with summary Rosetta energy statistics.
Intended uses include:
- Training and benchmarking machine learning models for pHLA binding affinity prediction
- Evaluating computational docking and scoring methods against experimental binding data
Dataset Structure
pHLA_binding/
├── README.md
├── metadata.csv # Master table — one row per IEDB measurement
└── structures/
├── A0101/
│ ├── FHEFLSSKL.silent
│ ├── GILGFVFTL.silent
│ └── ...
├── A0201/
└── ...
Each silent file contains the full 25-decoy ensemble for a single peptide–allele pair, including embedded Rosetta energy scores. Allele directory names use filesystem-safe notation (e.g. A0101/ for HLA-A*01:01), and silent files are named after the peptide sequence. The allele column in metadata.csv contains the standard notation (A*01:01).
Metadata Fields
| Column | Description |
|---|---|
allele_iedb |
Allele name in IEDB format (e.g. HLA-A_01_01) |
allele |
Standard allele notation (e.g. A*01:01) |
peptide |
Peptide amino acid sequence |
peptide_length |
Length of peptide in residues |
measurement_type |
IC50 or Kd |
measurement_value |
Quantitative binding measurement |
measurement_units |
Units of measurement (nM) |
assay_method |
Assay method as reported in IEDB |
assay_response |
Full assay response description from IEDB |
pubmed_id |
PubMed ID of the source publication |
parent_protein |
Source protein of the peptide |
protein_accession |
UniProt/GenBank accession of source protein |
source_organism |
Organism of origin |
assay_pdb_id |
Experimental PDB ID from IEDB (if available) |
flagged |
Whether entry was flagged during IEDB data cleaning |
num_decoys |
Number of decoy structures in the silent file (typically 25) |
rosetta_best_score |
Minimum total_score across 25 decoys (REU), extracted from silent file |
rosetta_mean_score |
Mean total_score across 25 decoys (REU), extracted from silent file |
pdb_dir |
Relative path to the peptide silent file within the dataset |
Dataset Statistics
| Metric | Count |
|---|---|
| Total measurements | 49,924 |
| Unique alleles | 37 |
| Unique peptides | 14,077 |
| IC50 measurements | 13,942 |
| Kd measurements | 35,982 |
| Flagged entries | 16 |
| Total silent files | 49,924 |
| Total decoy structures | 1,237,250 |
IEDB Data Curation
Binding affinity data were retrieved from a local copy of the IEDB bulk download (mhc_ligand_full.csv) and processed using a custom Python pipeline (IEDBTestPipeline.py). The curation procedure is described below.
1. Retrieval and Assay Filtering
The full IEDB MHC ligand table was read in chunks and filtered to retain only entries belonging to HLA-A or HLA-B alleles with quantitative binding measurements. Rows were retained only if they reported one of two assay response types:
- Half maximal inhibitory concentration (IC50)
- Dissociation constant (Kd)
Variant labels in the IEDB (e.g., dissociation constant KD (~EC50), dissociation constant KD (~IC50)) were normalized to a single canonical label (dissociation constant (KD)) prior to filtering. Entries missing either a quantitative measurement value or assay units were dropped.
2. Per-Allele Deduplication
After filtering, records were grouped by allele. Within each allele, duplicate entries for the same epitope (identified by IEDB Epitope IRI) were resolved separately for IC50 and Kd measurements using the following decision rules, applied in order:
| Scenario | Action |
|---|---|
| Two entries, one lacks a PubMed ID | Retain the entry with a PubMed ID; drop the other |
| Two entries, both lack PubMed IDs, values differ by ≤10 nM | Retain one entry (first occurrence) |
| Two entries, both lack PubMed IDs, values differ by >10 nM | Drop both entries |
| Two entries, both have PubMed IDs, values differ by <10 nM | Retain one entry (first occurrence) |
| Two entries, both have PubMed IDs, values conflict (≥10 nM difference) | Flag both for manual review |
| More than two entries | Drop entries lacking PubMed IDs first; if >2 remain, retain the entry closest to the median measurement value |
| Any other ambiguous case | Flag for manual review |
Entries that could not be unambiguously resolved were written to a separate flagged_IEDB_data.csv file for each allele and excluded from the cleaned dataset. These correspond to the flagged = True entries in metadata.csv.
3. Sequence-Level Filtering
After deduplication, peptide sequences containing the + character (used by IEDB to denote non-canonical or modified amino acids) were excluded from the final FASTA output and downstream structure generation.
4. Outputs per Allele
For each allele, the pipeline produced:
{allele}_cleaned_IEDB_data.csv— deduplicated, unflagged entries retained for structure modeling{allele}_flagged_IEDB_data.csv— ambiguous entries excluded from modeling but retained for reference{allele}_IEDB_data.fasta— peptide sequences in FASTA format for input to Rosetta FlexPepDock
These per-allele files were generated in filesystem-safe allele directories (e.g., HLA-A_01_01/ for HLA-A*01:01) within the working directory at the time of pipeline execution.
5. Manual Review Checkpoint
By default, the pipeline pauses after generating per-allele cleaned and flagged CSVs to allow manual literature review of flagged entries before structure generation proceeds. In this dataset, flagged entries were reviewed and those confirmed as erroneous or unresolvable were excluded. The --skipReview flag bypasses this checkpoint when manual review is not required.
Computational Methods
3D structures were generated using Rosetta FlexPepDock with 25 decoys per peptide–allele pair. Input structures were prepared by threading the peptide sequence of interest onto a template pHLA structure and performing flexible peptide docking.
All decoy structures and their associated Rosetta energy scores are stored in per-peptide Rosetta silent files (structures/{allele}/{peptide}.silent). Scores are reported as total_score (Rosetta Energy Units, REU) and are embedded directly in the silent file alongside the decoy coordinates. Summary statistics (min, mean) across the 25-decoy ensemble are precomputed and included in metadata.csv. Individual decoy structures can be extracted from silent files using extract_pdbs from the Rosetta toolkit.
Known Limitations and Caveats
Binding measurement caveats:
- IC50 values show large spikes at 20,000 nM and 70,000 nM, consistent with assay detection limits. These values should be treated as censored (i.e. greater than the reported value) rather than exact measurements.
- Kd values show analogous saturation at 5,000 nM and 20,000 nM for the same reason.
- IC50 and Kd are not directly comparable and have not been normalized or converted between each other. Both are retained with
measurement_typeindicating which was recorded.
Structure caveats:
- All 3D structures are computationally generated; no experimental validation has been performed.
- RMSD values embedded in silent files are calculated relative to the threaded template input, not to any experimental reference structure, and should not be interpreted as a measure of model accuracy.
- The best-scoring Rosetta decoy is not guaranteed to represent the native-like conformation.
Coverage caveats:
- Allele representation is highly uneven:
A*02:01accounts for9,500 entries (19% of the dataset), while several alleles have fewer than 10 entries. - The dataset covers HLA class I only (HLA-A and HLA-B). HLA-C and class II alleles are not included.
- The
assay_pdb_idcolumn references experimental structures deposited in the PDB as recorded by IEDB; these structures are not included in this dataset.
License
This dataset is released under CC BY 4.0. You are free to share and adapt the material for any purpose, provided appropriate credit is given.
Experimental binding data is sourced from the Immune Epitope Database (IEDB), which is also available under CC BY 4.0. Please cite IEDB if you use this dataset:
Vita R, Mahajan S, Overton JA, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Research. 2019;47(D1):D339–D343. https://doi.org/10.1093/nar/gky1006
Usage Example
import pandas as pd
from pathlib import Path
# Load metadata
df = pd.read_csv("metadata.csv")
# Filter to unflagged IC50 entries below detection limit
df_clean = df[
~df["flagged"] &
(df["measurement_type"] == "IC50") &
(df["measurement_value"] < 20000)
]
print(f"{len(df_clean)} clean IC50 entries")
print(f"Alleles: {df_clean['allele'].nunique()}")
print(f"Unique peptides: {df_clean['peptide'].nunique()}")
# Locate the silent file for a specific peptide-allele pair
silent_file = Path("structures/A0101/FHEFLSSKL.silent")
print(f"Silent file exists: {silent_file.exists()}")
# To extract individual PDB structures, use Rosetta's extract_pdbs:
# extract_pdbs.linuxgccrelease -in:file:silent structures/A0101/FHEFLSSKL.silent
- Downloads last month
- 2,057